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To date cytomorphology has remained the corner-
stone of diagnosis and provided the basis for the first 
widely accepted classification of acute leukemias (AL) that 
was developed by the efforts of French-American-British 
(FAB) group of hematologists [1]. Subsequent modifica-
tion of the FAB classification system [2] has also included 
cytochemistry and immunophenotypic analyses of blood 
and bone marrow blast cells. In recent years, cytogenetic 
and molecular techniques have provided deeper insights 
into the biology of specific subtypes of AL [3, 4].
According to the new WHO classification the diag-
nosis of leukaemia should be based on the complex 
of clinical, morphological and immunophenotypical 
findings supplemented by the data of molecular biol-
ogy and genetics of blast cells [5, 6]. In our opinion this 
classification, must be considered as an up-to-date 
reflection of the current, still incomplete understanding 
of biology of different forms of acute myeloid (AML) 
and acute lymphoblastic (ALL) leukaemia.
AL as well as other tumors of haematopoietic and 
lymphoid tissues represents the clonal processes. 
The blast cells infiltrating the bone marrow, which are 
detected in the peripheral blood and in the tissues, 
are the descendents of the single hematopoetic 
stem cell (HSC) or committed progenitor cells (CPC) 
undergoing the malignant transformation. The recent 
data suggest that several forms of AML as well as CML 
develop as a result of mutations accumulated in HSC.
The immunophenotype of these leukaemic stem cells 
(LSC) in different types of leukaemia was delineated 
[7, 8]. The suggested immunophenotype of LSC in AML 
is CD34+ CD38- CD90- CD123+ CD117- CD71- HLD-DR-, 
while in ALL the suggested immunophenotype is CD34+ 
CD38- Lin- CD10- CD19-. Moreover, a universal phenotype 
of LSC may not exist and patient-to-patient variations in 
cell surface antigen expression may be the rule.
Malignant changes rarely occur in HSC prior to its 
commitment to either the myeloid or lymphoid lineage. 
ALL is a malignant disorder of B- or T- lymphoid pro-
genitor cells with peak of prevalence between the ages 
of 2 and 5 years. AML is the most common form of AL in 
adults, accounting for over 80% of all AL. AML is a het-
erogeneus group of leukaemias that arise in precursors 
of myeloid, erythroid, megakaryocytic and monocytic 
cell lineages. AML and ALL are divided into a number of 
different subtypes and the correct diagnosis is based 
upon a wide range of clinical, morphologic methods 
as well as novel technique of immunophenotyping, 
cytogenetics and molecular biology.
We believe that the standard panel for classifica-
tion of AL [5, 6] should be supplemented with several 
new markers allowing us to identify more precisely the 
different forms of the disease.
Unfortunately, up to the present, only cytomorpho-
logy and several cytochemical techniques were routinely 
used for the diagnostic purposes in oncohematology in 
the vast majority of the hematological clinics in Ukraine. 
In 1993, the Reference Center was set up as a public ser-
vice at R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine with the aim 
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of precise diagnosis of the haematopoietic malignan-
cies based on cytomorphology, enzyme cytochemistry 
and immunophenotyping in accordance with FAB, EGIL 
(European group for the immunological characterization 
of leukaemias) and WHO classifications.
This study included 1742 patients with AML and ALL, 
residents of Kyiv city and 20 regions of Ukraine. The bone 
marrow and blood smears were sent at diagnosis to Refe-
rence Center from February 12, 1996 to June 1, 2010.
The analysis was based on May-Grünwald-Giemsa 
(MGG) stain, myeloperoxidase reaction (MPO), acid 
non-specific esterase using alpha-naphtyl-acetate 
(acNSE, sodium fluoride-sensitive), chloracetate-
esterase (CAE) and acid phosphatase (AP) stain. Gly-
cogen was assayed cytochemically by PAS-reaction. 
All stainings were performed routinelly according to 
standard procedures [3, 9–11]. Immunocytochemical 
techniques (APAAP, LSAB) and broad panel of mono-
clonal antibodies (MoAbs) against lineage specific and 
differentiation antigens of leukocytes were employed 
for immunophenotyping leukaemic blast cells directly 
in blood and bone marrow smears.
Acute myeloid leukaemias. The defining criterion 
for AML was 20% and more myeloblasts in peripheral 
blood or bone marrow. For the sub-classification of 
AML the primary basis were the morphological and 
enzyme-cytochemical/ immunocytochemical features 
of leukaemic cells [12].
Different types of AML were defined immunologi-
cally by the expression of the following cell surface and 
cytoplasmic antigens: markers of HSC and progenitor 
cells (CD34, CD38, CD117, HLA-DR), granulocytic 
markers (CD13, CD15, CD33, cytoplasmic MPO), 
monocytic markers (CD11c, CD14, CD4, CD11b), 
megakaryocytic markers (CD41, CD61), erythroid 
marker (glycophorin A).
The series of 1271 consecutive patients with AML 
were classified by the WHO system into such entities: 
AML with minimal differentiation; AML without matura-
tion; AML with maturation; acute monoblastic and mono-
cytic leukaemia; acute promyelocytic leukaemia; acute 
erytroid leukaemia; acute megakaryocytic leukaemia; 
blastic plasmacytoid dendritic cell neoplasm (BPDC).
Immunocytochemical study was required especial-
ly to establish the diagnosis of AML with minimal dif-
ferentiation, acute megakaryoblastic leukaemia, acute 
erythroid leukaemia and AL of ambiguous lineage.
AML with minimal differentiation is an AML without 
morphologic and cytochemical evidence of differen-
tiation. Blast cell in most cases (19 patients) expressed 
CD34, CD38, CD13 and CD117 antigens. Expression of 
CD7 has been seen in 13 cases. MPO was negative in 
blast cells by cytochemistry, but the result of detection 
of intracytoplasmatic MPO antigens in blast cells was 
positive by immunocytochemictry with anti-MPO MoAbs.
AML without maturation (28 patients) was 
characterized by MPO-positive blasts (Fig. 1) and 
expression CD13, CD33 and CD117 antigens. CD34 
and HLA-DR were positive in 19 patients. Expression 
of CD7 was registred in 8 and CD56 in 3 of cases.
a
b
Fig. 1. Acute myeloid leukaemia without maturation, bone 
marrow smear: a, the cells predominantly myeloblasts; b, my-
eloblasts with myeloperoxidase activity.
AML with maturation (126 patients). The blast 
cells in our study expressed such myeloid-associated 
antigens: CD13 (114 patients), CD33 (108), CD15 
(109). In a fraction of blasts expression of HLA-DR and 
CD34 was revealed.
Acute myelomonocytic leukaemia (448 patients) 
(Fig. 2) showed population of blast expressing myeloid 
antigens CD13, CD33, CD15 and population of leukae-
mic cells with markers of monocytic differentiation: 
CD14, CD4, CD11b, CD11c. In most cases blast cells 
were positive for HLA-DR and in 287 patients for CD7.
Fig 2. Acute myelomonocytic leukaemia associated with inv(16)
(p13.1;q22) and abnormal eosinophils. 
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Acute monoblastic and monocytic leukaemia 
(498 patients) (Fig. 3). Blast cells were acNSE positive, 
expressed HLA-DR, myeloid antigens CD13, CD15 
and markers of monocytic differentiation CD14, CD4, 
CD11b, CD11c, CD68. In 104 cases expression was 
found of CD7 and CD56. MPO was expressed more 
often in acute monocytic leukaemia.
Fig. 3. Acute monoblastic leukaemia.
Acute promyelocytic leukaemia (116 patients) 
(Fig. 4) was characterized by absence of HLA-DR, 
CD34 and CD15 expression, weak positive reaction 
with MoAbs to CD117.
Acute erythroid leukaemia. The blast cells were 
negative for HLA-DR, CD34 and MPO. Expression of 
glycophorin A was detected in 16 cases with more dif-
ferentiated leukaemic cells and antigen CD36 that may 
be expressed also by monocytes and megakaryocytes 
in 26 patients. The need of an early marker specific for 
the erythroid lineage would be stressed as it is likely 
that cases resulting from leukaemic transformation of 
primitive erythroid cells were underdiagnosed.
Acute megakaryoblastic leukaemia was diag-
nosed in 17 patients.
Megakaryoblasts typically expressed CD41 (glyco-
protein IIb/IIIa), CD61 (glycoprotein IIIa) antigens and 
CD36. Reactions for CD34 and HLA-DR were negative.
Blastic plasmacytoid dendritic cell neoplasm. 
The blast cells in BPDC were negative with myeloper-
oxidase and weak positive with acNSE stains. Neo-
plastic cells expressed CD4 and CD56 antigens. In 
2 of 3 cases on the cell surface membrane had heen 
demonstrated expression of CD7, CD38 and CD71. 
Cells were CD34 and CD117 negative.
Future studies will be addressed to investigate 
whether an immunological classification of AML is pos-
sible in relation to the various AML groups defined by 
cytogenetics and molecular features. Thus data will be 
collected to disclose the most common immunologi-
cal phenotypes, if any, in cytogenetically defined AML 
subgroups with t(8;21), inv(16), t(15;17) or t(9;11) [12].
Acute lymphoblastic leukaemias. Acute lympho-
blastic leukaemias (ALL) (463 patients) was broadly 
classified into B-lineage and T-lineage ALL. In total 387 
patients with B-ALL and 76 with T-ALL in our Reference 
Center were examined.
a
b
c
d
Fig. 4. Acute promyelocytic leukaemia with t(15;17)(q22;q12); 
PML-RARA, bone marrow: a, hypergranular type; b, micro-
granular variant; c, myeloperoxidase reaction showing intensely 
positive abnormal promyelocytes; d, acid non-specific esterase 
stain. The promyelocytes are intensely reactive.
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B-lineage ALL was defined by the expression of 
the following three early B-cell markers: CD19, cyto-
plasmic CD79a and cytoplasmic CD22. According to 
the degree of B-lymphoid differentiation of the blast 
cells, four subtypes of B-lineage ALL designated from 
B-I to B-IV were established, namely B-I (pro-B ALL): 
CD34+/-, HLA-DR+, CD19+, cyCD22+, cyCD79a+; B-II 
(common ALL): CD34+/-, HLA-DR+, CD19+, cy/sCD22+, 
CD79a+, CD10+; B-III (pre-B ALL): HLA-DR+, CD19+, 
CD22+, CD79a+, CD10+/-,CD20+, cyIgM+; B-IV (B-cell 
ALL): HLA-DR+, CD19+, CD22+, CD79a+, CD10+/-, 
CD20+, sIgM+, cyκ+ or cyλ+  (Fig. 5, 6).
Fig. 5. The lymphoblasts in pro-B-ALL (B-I) are positive for the 
antigen CD34. Bone marrow smears. 
a
b
Fig. 6. Common acute lymphoblastic leukaemia (B-II), bone 
marrow: a, lymphoblasts with a high nuclear/cytoplasmic ration; 
b, the lymphoblasts are positive for CD19 antigen.
The modern concept of LSC allows one to analyze 
in more depth the mechanisms of leukaemic transfor-
mation of target cells in AL of the closely related origin, 
namely pro-B ALL vs. acute monoblastic leukaemia, 
acute erytroid leukaemia vs. acute megakaryoblastic 
leukaemia. The similarity of immunophenotype and 
cytogenetic abnormalites in blast cells in pro-B ALL 
and acute monoblastic leukaemia seem to be the hint 
explaining the cases of acute monoblastic leukaemia 
as a recurrence of leukaemia in children with originally 
diagnosed pro-B ALL.
T-lineage ALL observed in our patients were also 
divided into four variants, namely T-I (pro-T ALL): HLA-
DR+/-, CD34+/-, CD7+, cyCD3+, CD5+/-; T-II (pre-T ALL): 
CD7+, cy/sCD3+, CD5+, CD2+,CD8+; T-III (with cortical 
thymocytes phenotype): CD7+, CD3+, CD5+, CD2+, 
CD1a+, CD4/8+; T-IV (mature T ALL): CD7+, CD3+,CD5+, 
CD2+, CD4+ or CD8+.
The majority of acute leukaemias parameters (the 
ratio of ALL to AML; frequency of B- and T-cell ALL; age 
structure of ALL; the percentage of different variants 
of of B-cell origin; the frequency of aberrant expres-
sion of myeloid antigens on blast cells from AML) are 
comparable with corresponding data from USA and 
most European countries [13, 14].
Immunocytochemical studying is required to 
diagnose acute leukaemias of ambiguous lineage 
that show no clear evidence of lineage differentiation 
(acute undifferentiated leukaemia) or those with blasts 
that express markers of more than one lineage (mixed 
phenotype acute leukaemias).
Today we continue the attempts for precise char-
acterization of this rare group of acute leukaemias.
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